A Phase II Study of Talimogene Laherparepvec for Patients With Inoperable Locoregional Recurrence of Breast Cancer

Abstract excerpt

<title>Abstract</title> <p><bold>Purpose: </bold>Talimogene laherparepvec (T-VEC) is an immunotherapy that generates local tumor lysis and systemic antitumor immune response. We studied the efficacy of intratumoral administration of T-VEC as monotherapy for inoperable locoregional recurrence of breast cancer.<bold>Methods: </bold>Patients had to have cutaneous, subcutaneous, or nodal tumors injectable with T-VEC....

Topics

Open a Topic to create a Post that cites this publication.

• CAR-T cell therapy research
• Drug Interactions
• Health Care Costs
• Melanoma
• Oncolytic Virotherapy
• Oncolytic Viruses
• Patient Selection
• Virus-based gene therapy research

Identifiers and source

Literature Corpus work

76ecd673-35ff-5a8d-9596-a78a64e73a81

DOI

10.21203/rs.3.rs-531229/v1